Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
The current price of ADYX is $0.00 USD — it has increased by +9,900% in the past 24 hours. Watch Adynxx stock price performance more closely on the chart.
What is Adynxx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adynxx stocks are traded under the ticker ADYX.
What is Adynxx revenue for the last year?▼
Adynxx revenue for the last year amounts to 2.22M USD.
What is Adynxx net income for the last year?▼
ADYX net income for the last year is -8.42M USD.
Does Adynxx pay dividends?▼
Yes, ADYX dividends are paid en. The last dividend per share was 1.05 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Adynxx have?▼
As of June 15, 2026, the company has 6 employees.
In which sector is Adynxx located?▼
Adynxx operates in the Health & Wellness sector.
When did Adynxx complete a stock split?▼
The last stock split for Adynxx was on April 18, 2019 with a ratio of 1:6.
Where is Adynxx headquartered?▼
Adynxx is headquartered in San Francisco, United States.